FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84090
News■ Unclear/unknown
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Preclinical ATNM-400 data is early-stage and the excerpt lacks efficacy numbers or listed peers.
Early oncology data, long path to market
CATALYST TO WATCH
Trial advancement or partnership
MAIN RISK
Preclinical results often fail to translate
FULL DISPATCH
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal cancer data demonstrate ATNM-400's potential to enhance responses to standard-of-care...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
→CORRELATIONshares Healthcare
Health Care and Crude Led the Week While Tech Lost Its Grip2026-10-16 13:10 UTC
Health Care and Crude Led the Week While Tech Lost Its Grip2026-10-16 13:10 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. — AstraZeneca2026-10-16 12:00 UTC
New Phase 3 trial: A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. — AstraZeneca2026-10-16 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.